Croconazole in the treatment of tinea pedis

Beierdörffer, H; Michel, Gudrun; Kehr, K.

doi:10.1111/j.1439-0507.1995.tb00028.x

Cited by 3 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Two weeks of once‐daily treatment with luliconazole, a newly developed imidazolyl antifungal agent, has also been demonstrated to be effective for the treatment of tinea pedis 77 . Other once‐daily topical treatments that have also been shown to be effective in patients with tinea pedis include 2% ketoconazole cream, 78 1% croconazole cream, 79 1% butenafine cream, 80 0·77% ciclopriox gel, 81 and 0·5% or 2% amorolfine spray 82 . Terbinafine 1% cream or gel has also been used effectively in once‐daily short‐course therapy for the treatment of tinea pedis.…”

Section: Do Approaches Employed To Improve Adherence To Oral Therapy mentioning

confidence: 99%

Adherence to topical dermatological therapy: lessons from oral drug treatment

Gupta

Mallefet

Kress

et al. 2009

British Journal of Dermatology

View full text Add to dashboard Cite

Patients are remarkably nonadherent to medical treatment regimens across all diseases and classes of therapy, and it has been estimated that nonadherence to drug treatment is responsible for as many as 10% of all hospital admissions. Nonadherence to treatment also has significant negative effects on treatment outcomes across a wide range of diseases. Patient-related factors such as age, ethnicity, literacy (including health literacy), health beliefs, and socioeconomic conditions have been shown to influence adherence to oral therapy. Medication-related factors, such as regimen complexity and duration of treatment, also impact on adherence. Variables that significantly influence adherence to oral drugs have similar effects on adherence to topical therapy. Both educational and psychological interventions along with simplification of dosing regimens can significantly improve adherence to oral therapy and limited evidence indicates that these approaches are also effective in patients receiving topical therapy. There is very little information about the effects of dosing regimens on adherence to topical medical therapy. The advent of new drug formulations that permit once-daily or single-dose drug application will, however, permit evaluation of different topical treatment regimens on adherence and treatment outcomes in patients with dermatological disease.

show abstract

Section: Do Approaches Employed To Improve Adherence To Oral Therapy mentioning

confidence: 99%

Adherence to topical dermatological therapy: lessons from oral drug treatment

Gupta

Mallefet

Kress

et al. 2009

British Journal of Dermatology

View full text Add to dashboard Cite

show abstract

Screening of Antifungal Azole Drugs and Agrochemicals with an Adapted alamarBlue-Based Assay Demonstrates Antibacterial Activity of Croconazole against Mycobacterium ulcerans

Scherr

Röltgen

Witschel

et al. 2012

Antimicrob Agents Chemother

View full text Add to dashboard Cite

An alamarBlue-based growth inhibition assay has been adapted for the thermosensitive and slow-growing pathogen Mycobacterium ulcerans. The standardized test procedure enables medium-throughput screening of preselected compound libraries. Testing of a set of 48 azoles with known antifungal activity led to the identification of an imidazole antifungal displaying an inhibitory dose (ID) of 9 M for M. ulcerans. Mycobacterium ulcerans is the causative agent of Buruli ulcer, a disfiguring disease characterized by the formation of chronic, necrotizing skin ulcers. Buruli ulcer is a major public health problem, primarily in West Africa, where it typically affects impoverished inhabitants of remote rural areas (25). Surgical excision of lesions was the only therapeutic option until the World Health Organization released provisional guidelines in 2004 advising an 8-week combination chemotherapy regimen of oral rifampin and intramuscular streptomycin (26). Implementation of this regimen has significantly reduced recurrence rates. However, there are some drawbacks associated with the administration of these antibiotics. Streptomycin requires daily injections and is potentially nephrotoxic and ototoxic (5). Monotherapy with rifampin is not a solution because resistance can develop rapidly (14). While studies on fully oral regimens replacing streptomycin with clarithromycin yielded promising results (2, 6), identification of new drugs that could replace rifampin would be most desirable.Since lead compounds identified by target-based approaches are frequently inactive against the pathogen grown in culture (4, 13, 19), whole-cell assays are highly valuable in the search for new antibiotics. The extremely low growth rate of M. ulcerans complicates the identification of potentially effective new scaffolds. In this report, we describe the development of an alamarBlue microplate assay which enables screening of compounds for their activity against M. ulcerans within 10 days. Here we report results of a pilot study performed with this medium-throughput screening procedure. Testing of a preselected group of azoles led to the detection of compounds with potency against M. ulcerans.alamarBlue-based assays have been shown to be powerful and sensitive tools for the identification of growth-inhibitory compounds irrespective of the underlying mode of action and chemical classification. They are widely used for screens with both mammalian cells and microorganisms, including mycobacterial species (4,7,9,10,13,19). In order to develop a suitable test format for M. ulcerans, the specific growth features, a long generation time of about 72 h and a low optimal growth temperature of 28 to 32°C, had to be taken into account. To reduce the problem that M. ulcerans tends to aggregate when grown in liquid medium, the inoculum was prepared in BacT/Alert culture bottles supplemented with enrichment medium according to the manufacturer's protocol (bioMérieux). NM20/02, a M. ulcerans strain isolated in 2002 from the Buruli ulcer lesion of a Ghanaian pati...

show abstract

An Overview of Topical Antifungal Therapy in Dermatomycoses

Gupta

Einarson

Summerbell

et al. 1998

Drugs

116

View full text Add to dashboard Cite

Dermatophytes cause fungal infections of keratinised tissues, e.g. skin, hair and nails. The organisms belong to 3 genera, Trichophyton, Epidermophyton and Microsporum. Dermatophytes may be grouped into 3 categories based on host preference and natural habitat. Anthropophilic species predominantly infect humans, geophilic species are soil based and may infect both humans and animals, zoophilic species generally infect non-human mammals. It is important to confirm mycologically the clinical diagnosis of onychomycosis and other tinea infections prior to commencing therapy. The identity of the fungal organism may provide guidance about the appropriateness of a given topical antifungal agent. Special techniques may be required to obtain the best yield of fungal organisms from a given site, especially the scalp and nails. It is also important to realise the limitations of certain diagnostic aids e.g., Wood's light examination is positive in tinea capitis due to M. canis and M. audouinii (ectothrix organisms); however, Wood's light examination is negative in T. tonsurans (endothrix organism). Similarly, it is important to be aware that cicloheximide in culture medium will inhibit growth of non-dermatophytes. Appropriate media are therefore required to evaluate the growth of some significant non-dermatophyte moulds. For tinea infections other than tinea capitis and tinea unguium, topical antifungals may be considered. For effective therapy of tinea capitis an oral antifungal is generally necessary. Similarly, oral antifungals are the therapy of choice, especially if onychomycosis is moderate to severe. Furthermore, where the tinea infection involves a large area, in an immunocompromised host or if infection is recurrent with poor response to topical agents, then oral antifungal therapy may be necessary. Topical antifungal agents may be broadly divided into specific and nonspecific agents. The former group includes the polyenes, azoles, allylamines, amorolfine, ciclopirox and butenafine. Generally the topical agent is available as a cream, sometimes for use intravaginally. Less commonly, the formulation may be in the form of a powder, lacquer, spray, gel or solution. Many of these agents have a broad spectrum of activity, being effective against dermatophytes, yeasts and Malassezia furfur. For the treatment of tinea corporis, tinea cruris tinea versicolor and cutaneous candidosis, once or twice daily application may be required, the most common duration of therapy being 2 to 4 weeks. For tinea pedis the most common treatment duration is 4 to 6 weeks.

show abstract

Croconazole in the treatment of tinea pedis

Cited by 3 publications

References 11 publications

Adherence to topical dermatological therapy: lessons from oral drug treatment

Adherence to topical dermatological therapy: lessons from oral drug treatment

Screening of Antifungal Azole Drugs and Agrochemicals with an Adapted alamarBlue-Based Assay Demonstrates Antibacterial Activity of Croconazole against Mycobacterium ulcerans

An Overview of Topical Antifungal Therapy in Dermatomycoses

Contact Info

Product

Resources

About